Autoimmune hyperlipidemia
Overview
Characterized by major hypertriglyceridemia, an abnormally high level of fat in the blood, due to autoantibodies preventing a specific type of protein (chylomicrons) in the plasma from properly circulating and transporting dietary lipids throughout the body.
Common Symptoms
At this time, more research is necessary. It remains unclear how much overlap there is between the autoimmune and genetic forms of the condition, the latter of which has been linked to symptoms of heart issues.
Coexisting Diseases and Conditions
Risk Factors and Prevalence
Researchers have yet to discover risk factors for autoimmune hyperlipidemia. This is a field of study that needs more investigation.
Recent Research
- Highly efficacious, long-term, triglyceride lowering with rituximab therapy in a patient with autoimmune hypertriglyceridemia (2018)
- Anti-lipoprotein lipase antibody-associated autoimmune hypertriglyceridaemia in a patient with systemic lupus erythematosus (2022)
- Acquired marked hypertriglyceridemia with anti‐GPIHBP1 antibodies (2020)
- Severe acquired hypertriglyceridemia following COVID-19 (2021)
Sources
- Article Sources
American Journal of Managed Care. (n.d.). Epidemiology and Management of Hyperlipidemia. AJMC. https://www.ajmc.com/view/epidemiology-and-management-of-hyperlipidemia-article
Baptist Health. (n.d.). Hyperlipidemia Signs, Symptoms & Treatment: Baptist Health. Baptist Health. https://www.baptisthealth.com/services/heart-care/conditions/hyperlipidemia.
Pruneta, V., Moulin, P., Labrousse, F., Bondon, P.-J., Ponsin, G., & Berthezene, F. (1997, March 1). Characterization of a New Case of Autoimmune Type I Hyperlipidemia: Long-Term Remission under Immunosuppressive Therapy1. OUP Academic. https://academic.oup.com/jcem/article/82/3/791/2656302